Study wrapper · #597
The CD36-PPARγ Pathway in Metabolic Disorders.
Editor's note
This narrative review examines the CD36-PPAR-gamma axis in metabolic disorders and highlights hexarelin as a potent inducer of PPAR-gamma through the scavenger receptor CD36. It synthesizes preclinical work suggesting this GHRP-CD36-PPAR-gamma pathway influences atherosclerosis, hepatic cholesterol synthesis, and fat-cell mitochondrial biogenesis. As a review, it is a helpful map of why hexarelin has metabolic effects that are partly independent of growth hormone, useful editorial context rather than primary evidence. Readers should note it aggregates mostly cell and animal studies and does not weigh clinical outcomes. The evidence it summarizes is mechanistic and preclinical; human data would be needed before drawing clinical conclusions about hexarelin's metabolic role.
Plain-language abstract
This is a review article, not a new experiment. It explains how a receptor called CD36 and a metabolism-regulating protein called PPAR-gamma work together to control fat and energy handling, and how they go wrong in metabolic diseases. A central point is that hexarelin, a growth-hormone-releasing peptide, can switch on PPAR-gamma by acting through CD36. The authors summarize animal and cell studies suggesting this pathway affects artery plaque, cholesterol production in the liver, and the energy machinery of fat cells. The article is useful for understanding why hexarelin may affect metabolism beyond its growth-hormone action. Because it reviews mostly preclinical work, these ideas would still need human studies before any clinical conclusions could be drawn.